论文部分内容阅读
应用东菱精纯克栓酶(DF-521)治疗发病<7d急性脑梗死40例,并与常规维脑路通治疗40例同期同类病人做对照.结果:治疗组治愈率25.0%,显著进步50.0%,进步15.0%,总显效75.0%,总有效率90.0%;对照组治愈率12.5%,显著进步27.5%,进步22.5%,显效率4O.O%,总有效率62.5%,两组比较差异显著.表明东菱精纯克栓酶治疗<7d急性期脑梗死疗效肯定,安全,值得临床推广应用.
Forty cases of acute cerebral infarction with onset of <7 days were treated with DF-521 and compared with 40 cases of the same type of conventional Venoruton.Results: The cure rate of treatment group was 25.0%, which was significantly improved 50.0%, progress 15.0%, the total effective rate was 75.0%, the total effective rate was 90.0%; the cure rate of the control group was 12.5%, significant improvement of 27.5%, 22.5% improvement, the effective rate was 40.0%, the total effective rate was 62.5% The difference was significant.It showed that Dongling Jing Ke thrombin enzyme treatment of acute cerebral infarction <7d affirmation, safe, worthy of clinical promotion and application.